InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

- Current share price for OCC : $0.730

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$199 Appendix 3B 12 Jan 2018 11:32AM $0.345 $0.730 risen by 111.59%
$199 Orthocell featured at Biotech Showcase in San Francisco 9 Jan 2018 9:28AM $0.350 $0.730 risen by 108.57%
$199 50% Patient Treatment Milestone in Human Nerve Trial 2 Jan 2018 8:29AM $0.340 $0.730 risen by 114.71%
$199 Share Purchase Plan Closing Date Extended 28 Dec 2017 11:27AM $0.340 $0.730 risen by 114.71%
$199 Appendix 3B and Notice Under Section 708A 20 Dec 2017 6:30PM $0.335 $0.730 risen by 117.91%
$199 Invitation to Participate in Share Purchase Plan 15 Dec 2017 3:22PM $0.350 $0.730 risen by 108.57%
$199 Notice Under ASIC Class Order CO 09/425 15 Dec 2017 3:17PM $0.350 $0.730 risen by 108.57%
$199 Orthocell Granted European Tendon Regeneration Patent 15 Dec 2017 9:36AM $0.350 $0.730 risen by 108.57%
$199 Orthocell Featured in CommSec Executive Series Interview 14 Dec 2017 10:04AM $0.350 $0.730 risen by 108.57%
$199 Placement and Share Purchase Plan 13 Dec 2017 10:01AM $0.385 $0.730 risen by 89.61%
$199 Trading Halt 11 Dec 2017 9:16AM $0.385 $0.730 risen by 89.61%
$199 Ortho-ATI Case Study Publication 8 Dec 2017 10:32AM $0.380 $0.730 risen by 92.11%
$199 Orthocell Commences Treatment of its 1,000th Patient 7 Dec 2017 9:58AM $0.380 $0.730 risen by 92.11%
$199 Orthocell Granted European Cartilage Regeneration Patent 1 Dec 2017 9:40AM $0.380 $0.730 risen by 92.11%
$199 Change of Director's Interest Notice - options expiry * 5 30 Nov 2017 6:01PM $0.380 $0.730 risen by 92.11%
$199 FDA Comprehensive Regenerative Medicine Policy Framework 27 Nov 2017 9:52AM $0.390 $0.730 risen by 87.18%
$199 Company Update Presentation 21 Nov 2017 8:28AM $0.380 $0.730 risen by 92.11%
$199 Results of Meeting 15 Nov 2017 5:31PM $0.380 $0.730 risen by 92.11%
$199 Orthocell Receives CE Mark for CelGro 9 Nov 2017 10:13AM $0.310 $0.730 risen by 135.48%
$199 Trading Halt 8 Nov 2017 9:56AM $0.310 $0.730 risen by 135.48%
$199 Appendix 4C - quarterly 31 Oct 2017 6:55PM $0.325 $0.730 risen by 124.62%
$199 Orthocell receives R&D tax incentive refund 24 Oct 2017 9:18AM $0.315 $0.730 risen by 131.75%
$199 Company Update Presentation 17 Oct 2017 8:19AM $0.300 $0.730 risen by 143.33%
$199 Orthocell Granted CelGro Patent Protection in Canada 16 Oct 2017 9:31AM $0.290 $0.730 risen by 151.72%
$199 Notice of Annual General Meeting/Proxy Form 13 Oct 2017 1:16PM $0.300 $0.730 risen by 143.33%

601 - 625 of 760 results

Page 25 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.